Genprex (NASDAQ:GNPX) Announces Quarterly Earnings Results

Genprex (NASDAQ:GNPX) issued its earnings results on Friday. The company reported ($9.40) earnings per share for the quarter, Zacks reports.

Genprex Stock Performance

Shares of Genprex stock traded down $0.56 during midday trading on Friday, reaching $4.31. 87,008 shares of the company’s stock traded hands, compared to its average volume of 61,742. Genprex has a 52 week low of $4.00 and a 52 week high of $1,210.00. The company has a market cap of $2.15 million, a price-to-earnings ratio of -0.01 and a beta of -0.88. The company’s 50 day simple moving average is $9.69 and its 200 day simple moving average is $25.41.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Wall Street Zen upgraded shares of Genprex from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Institutional Trading of Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP boosted its holdings in Genprex (NASDAQ:GNPX) by 11.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 340,056 shares of the company’s stock after buying an additional 35,661 shares during the period. Susquehanna International Group LLP owned approximately 27.20% of Genprex worth $58,000 as of its most recent SEC filing. 14.05% of the stock is owned by institutional investors and hedge funds.

Genprex Company Profile

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.